Table 3.
Predicted Helper T lymphocyte (HTL) epitopes of SARS-CoV-2 proteins utilized for the construction of a multi-epitope subunit vaccine.
| Epitope | Allele (score) | IC50 |
|---|---|---|
| ORF8 protein | ||
| HFYSKWYIRVGARKS | HLA-DRB1*07:01 (0.06) HLA-DRB1*01:01 (0.07) |
32.2 39.5 |
| DFLEYHDVRVVLDFI | HLA-DQA1*05:01/DQB1*02:01 (0.01) HLA-DQA1*01:01/DQB1*05:01 (0.5) |
276 101.9 |
| IHFYSKWYIRVGARK | HLA-DPA1*02:01/DPB1*01:01 (0.01) HLA-DPA1*03:01/DPB1*04:02 (0.02) HLA-DPA1*01:03/DPB1*02:01 (0.09) |
281.8 42.8 79.4 |
| nsp9 | ||
| KGLNNLNRGMVLGSL | HLA-DQA1*05:01/DQB1*03:01 (0.04) HLA-DQA1*01:02/DQB1*06:02 (0.62) |
62 95 |
| GPKVKYLYFIKGLNN | HLA-DPA1*01:03/DPB1*02:01 (0.01) HLA-DPA1*02:01/DPB1*05:01 (0.02) HLA-DPA1*02:01/DPB1*01:01 (0.52) |
61 79.7 109.3 |
| nsp3 | ||
| TAFGLVAEWFLAYIL | HLA-DQA1*05:01/DQB1*02:01 (0.01) HLA-DQA1*01:01/DQB1*05:01 (0.14) |
50 46.4 |
| AAIMQLFFSYFAVHF | HLA-DPA1*01:03/DPB1*02:01 (0.01) HLA-DPA1*01/DPB1*04:01 (0.01) HLA-DPA1*02:01/DPB1*01:01 (0.02) |
8.7 78.5 110.8 |
| endoRNAse | ||
| MEIDFLELAMDEFIE | HLA-DQA1*03:01/DQB1*03:02 (0.01) HLA-DQA1*05:01/DQB1*02:01 (0.03) HLA-DQA1*01:01/DQB1*05:01 (0.07) |
97.6 12.9 37.9 |
| GLAKRFKESPFELED | HLA-DPA1*01/DPB1*04:01 (0.02) HLA-DPA1*02:01/DPB1*05:01 (0.12) |
108.6 453 |
| ORF3a | ||
| ACFVLAAVYRINWIT | HLA-DRB1*07:01 (0.01) HLA-DRB1*01:01 (0.02) |
19.9 12.4 |
| membrane glycoprotein | ||
| ACFVLAAVYRINWIT | HLA-DQA1*05:01/DQB1*02:01 | 321.4 |
| KLIFLWLLWPVTLAC | HLA-DPA1*03:01/DPB1*04:02 (0.01) HLA-DPA1*02:01/DPB1*01:01 (0.52) HLA-DPA1*01:03/DPB1*02:01 (0.75) |
187.6 133.8 21.3 |
| DDQIGYYRRATRRIR | HLA-DRB1*01:01 (0.01) HLA-DRB1*07:01 (0.01) HLA-DRB3*01:01 (0.01) |
223 43 79.2 |
| nucleocapsid phosphoprotein | ||
| GKMKDLSPRWYFYYL | HLA-DPA1*01:03/DPB1*02:01 (0.08) | 194.7 |
The half-maximal inhibitory concentration (IC50) value was < 500 nm, which ensured a higher binding capability of selected epitopes to MHC molecules.